Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic ...

The company anticipates significant milestones in its STAT6 and IRF5 programs, which are expected to drive future growth. These developments are positioned to address a substantial market ...

This was primarily due to increased expenses related to investments in the STAT6 and TYK2 degrader programs, platform and discovery programs, as well as a rise in occupancy and related costs ...